Eli Lilly Makes Another In Vivo Genetic Medicines Move With $3.2B Kelonia AcquisitionNews DeskApril 20, 20260 Eli Lilly is expanding its reach in genetic medicines with a multi-billion dollar deal to acquire Kelonia Therapeutics, a startup…
Obsidian, Galera Merger Comes With $350M Infusion for Cancer Drug TrialsNews DeskApril 19, 20260 Obsidian Therapeutics is merging with Galera Therapeutics to advance clinical development of a pipeline led by a next-generation cell therapy…
Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to TumorsNews DeskApril 15, 20260 Antibody drug conjugates continue to be a robust area for research and dealmaking, and Eli Lilly’s latest move in this…